
Rember: Issues in design of a phase 3 disease modifying clinical trial of Tau aggregation inhibitor therapy in Alzheimer's disease
Claude WischikVolume:
5
Année:
2009
Langue:
english
DOI:
10.1016/j.jalz.2009.05.175
Fichier:
PDF, 40 KB
english, 2009